Does sermorelin work? It can produce a measurable growth hormone response when the pituitary is able to respond, but the adult human evidence is small, old and inconsistent beyond that biochemical signal. In one 14-day study, the higher of two tested regimens raised 24-hour growth hormone measures and IGF-1 in 10 older men. In another study of 11 older men, six weeks of a single nightly injection raised nocturnal growth hormone output but did not change IGF-1 or DEXA body composition. That is evidence of biological activity, not proof of a predictable visible result.
What sermorelin is and what “working” means
Sermorelin is the amidated 1–29 fragment of human growth hormone-releasing hormone, or GHRH. It does not supply growth hormone. It binds GHRH receptors in the pituitary and prompts the gland to release the body's own growth hormone in pulses. The distinction from injected HGH matters; sermorelin versus HGH owns that comparison in full.
There are three different questions hidden inside the word “working”:
- Did the pituitary respond? A sampled GH pulse or a structured stimulation test can show an acute response. A random GH value is hard to interpret because secretion is pulsatile.
- Did downstream signaling change? IGF-1 is more stable than GH and can help a clinician evaluate the trend over weeks, interpreted against age-adjusted ranges and the clinical context.
- Did a meaningful outcome change? Body composition, function or another agreed endpoint takes longer to assess and cannot be inferred from one higher lab value.
Those layers should not be collapsed into a promise that a sensation proves efficacy. The prescriber should define the endpoint before treatment and revisit it with repeat measurements.
Does sermorelin work in human studies?
The direct adult evidence is measured in dozens of participants per study — the largest, a six-month cognition trial, followed 89 older adults (Vitiello et al., Neurobiology of Aging 2006) — not hundreds or thousands. The studies also used research regimens that do not establish a personal prescription; the reviewing prescriber sets any actual dose and monitoring plan.
| Study | Who and how long | What changed | What did not, or what limits the result |
|---|---|---|---|
| Corpas et al., 1992 | 10 healthy older men completed two 14-day GHRH(1-29) periods; 9 young men were age comparators | At the higher tested regimen, mean 24-hour GH and GH peak area increased (both P<0.001), peak amplitude increased (P<0.05), and IGF-1 increased (P<0.005) | The lower regimen did not produce the same significant findings; there was no placebo group and no body-composition endpoint |
| Vittone et al., 1997 | 11 healthy men ages 64–76, treated for 6 weeks | Mean nocturnal GH release increased (P<0.02), as did peak area (P<0.006) and peak amplitude (P<0.05) | IGF-1 did not change; neither did weight, BMI, waist-to-hip ratio, DEXA muscle or fat, glucose measures or lipids |
| Khorram et al., 1997 | 19 adults ages 55–71 used a closely related modified GHRH(1-29) analog for 16 weeks after a 4-week saline period | IGF-1 rose within 2 weeks; lean body mass increased in men only at 16 weeks (P<0.05) | This was a modified analog, not sermorelin itself; women did not show the lean-mass finding and other body-composition measures did not change |
The Corpas trial in The Journal of Clinical Endocrinology & Metabolism and the Vittone study in Metabolism point in the same direction for GH release but not for IGF-1 or body composition. The 16-week Khorram study adds a months-long signal, but extrapolating it to compounded sermorelin is uncertain because its molecule had a stabilizing amino-acid substitution. For a goal-by-goal discussion, sermorelin benefits owns that separate question.
CJC-1295 with ipamorelin is another growth-hormone secretagogue strategy, but its evidence cannot be substituted for sermorelin data. A prescriber would need a separate rationale for considering that alternative.
How long does sermorelin take to work?
The studies give a range, not a countdown. A GH pulse is the earliest measurable response. In the Corpas study, 24-hour GH and IGF-1 differences were assessed after 14 days, and only the higher tested regimen reached significance. The related Khorram analog study detected an IGF-1 increase within two weeks. Vittone's once-nightly study is the important counterweight: nocturnal GH measures increased after six weeks, yet IGF-1 still did not.
Body composition belongs on a slower clock. Vittone found no DEXA change at six weeks. Khorram found a lean-mass increase only in men after 16 weeks, with no corresponding finding in women and no broad change across the other composition measures. These data do not establish a reliable month when a person should look or feel different. They show why a clinician may look for an early biochemical response over weeks and judge any composition trend over months.
The prescribed amount, timing and adjustment logic are outside this evidence page. Sermorelin dosage covers how those decisions are made without turning a study regimen into self-dosing instructions.
How a prescriber judges sermorelin results
A useful review starts with the reason treatment was considered and a baseline that can be compared fairly. Depending on the clinical context, the provider may follow IGF-1, relevant metabolic labs and a consistent body-composition method. GH itself is pulsatile, so one random reading may miss a pulse and create false confidence in either direction.
The response should also make physiological sense. A higher IGF-1 value is not automatically better, and a subjective change without a corresponding agreed endpoint may not answer whether the medication is doing what it was chosen to do. Persistently unchanged labs, an out-of-range result or tolerability concerns can all change the plan. Sermorelin side effects owns the adverse-effect and safety details.
The 2006 Walker paper is often described as evidence that sermorelin works, but PubMed classifies it as a two-page editorial, not a controlled trial. It argues that stimulating endogenous pulsatile GH may have theoretical advantages over supplying HGH directly; it does not provide an efficacy effect size. That distinction is important when weighing the Walker editorial in Clinical Interventions in Aging alongside the small trials.
Sermorelin's regulatory history
Sermorelin was not always outside the FDA approval pathway: Geref previously had diagnostic and pediatric short-stature indications. The manufacturer discontinued it in 2008, and the agency withdrew the applications effective June 18, 2009. In 2013, the FDA determined that Geref had not been withdrawn for reasons of safety or effectiveness, according to the official Federal Register notice.
Through Promise, sermorelin is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. It is made by a licensed compounding pharmacy for an individual prescription and has not undergone the agency's premarket review for safety, effectiveness and quality. Regulatory status is one input into a prescribing decision, not the whole of it. A licensed provider may still prescribe a compounded formulation when they judge it appropriate; that decision is between the patient and the doctor.
What a useful decision looks like
The honest reading is that sermorelin has demonstrated pituitary activity in small human studies, while downstream and body-composition responses have varied by regimen, duration, sex and molecule. It is reasonable for a prescriber to consider those signals, but not to present them as a guaranteed outcome or a fixed results calendar.
At Promise, a licensed provider reviews every request and prescribes only when sermorelin is medically appropriate; not everyone qualifies. If it is prescribed, the clinician defines what success means, selects the monitoring plan and decides whether the measured response justifies continuing.